tailieunhanh - Possible involvement of interleukin-18 in the pathology of hepatobiliary adverse effects related to treatment with ceritinib

Ceritinib demonstrated a statistically significant effect on the progression-free survival versus chemotherapy in patients with advanced anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) as the first therapy or after previous treatment with crizotinib and one or two prior chemotherapy regimens in global phase 3 studies | Possible involvement of interleukin-18 in the pathology of hepatobiliary adverse effects related to treatment with ceritinib

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN